**DP2: Annual General Mandate 2024**

On April 24, 2024, Central Pharmaceutical Joint Stock Company No2 announced General Mandate No. 01/2024/NQ-DPTW2 as follows:

‎‎Article 1. The Annual General Meeting of Shareholders in 2024 unanimously approved the Report on production and business results of the Board of Management in 2023, the Production and Business Plan, and the operational orientation of the Board of Management in 2024

* 1. The General Meeting of Shareholders unanimously approved the report on production and business results of Central Pharmaceutical Joint Stock Company No2 in 2023:
* Revenue: VND 193,220 million
* Profit after tax: VND -24,049 million

1.2. The General Meeting of Shareholders unanimously approved the production and business plan of Central Pharmaceutical Joint Stock Company No2 in 2024:

* Revenue: VND 200,000,000,000
* Profit after tax: VND 0

‎‎Article 2. The Annual General Meeting of Shareholders in 2024 unanimously approved the report on the activities of the Board of Directors in 2023 and the operational orientation of the Board of Directors in 2024.

1. The General Meeting of Shareholders unanimously approved the content of the report on the activities of the Board of Directors in 2023.
2. The General Meeting of Shareholders unanimously approved the operational orientation of the Board of Directors in 2024.
* Revenue: VND 200 billion
* Profit: not negative, strive for profitability.
* The Board of Directors has a specific plan to proactively seek and cooperate with reputable financial institutions and strategic investors to resolve debts with the Vietnam Development Bank (VDB).

‎‎Article 3. The Annual General Meeting of Shareholders in 2024 unanimously approved the Activity Report in 2023 and the activity plan for 2024 of the Supervisory Board.

1. The General Meeting unanimously approved the Report on the results of operations of the Supervisory Board in 2023.
2. The General Meeting unanimously approved the orientation and tasks of the Supervisory Board in 2024.

‎‎Article 4. The Annual General Meeting of Shareholders in 2024 unanimously approved the audited Financial Statements for 2023.

‎‎Article 5. The Annual General Meeting of Shareholders in 2024 unanimously approved the Proposal on selecting the Audit Company for the fiscal year 2024.

The General Meeting unanimously approved the Proposal on selecting the audit company to perform the audit of the Financial Statements for the fiscal year 2024 of Central Pharmaceutical Joint Stock Company No2, which is: Vietnam Auditing and Evaluation Co., Ltd. (VAE)

‎‎Article 6. The Annual General Meeting of Shareholders in 2024 unanimously approved the plan for dividend payment and allocation of funds in 2023.

The General Meeting unanimously approved the plan not to pay dividends in 2023 and not to allocate funds in 2023.

‎‎Article 7. The Annual General Meeting of Shareholders in 2024 unanimously approved the remuneration of the Board of Directors and the Supervisory Board in 2023; the remuneration level of the Board of Directors and the Supervisory Board in 2024.

1. The Meeting agreed to approve the remuneration for the Board of Directors and the Supervisory Board in 2023
* The total remuneration for the Board of Directors & Supervisory Board in 2023 is: VND 76,800,000
* Remuneration for the Board of Directors in 2023: VND 48,000,000
* Remuneration for the Supervisory Board in 2023: VND 28,800,000
1. The General Meeting unanimously approved the remuneration level of the Board of Directors and the Supervisory Board in 2024.
* Remuneration for the Board of Directors in 2024:
* Chair of the Board of Directors: VND 0/month.
* Members of the Board of Directors: VND 1,000,000/month.
* Remuneration for the Supervisory Board in 2024:
* Chief VND 1,000,000/month.
* Member: VND 700,000/month.

‎‎Article 8. Supplementary provisions

The General Meeting assigns the Board of Directors of Central Pharmaceutical Joint Stock Company No2 to immediately implement the production and business plan for 2024 and other related tasks in accordance with the provisions of the Enterprise Law and the Company's Charter.

The General Mandate consists of 04 pages, which was unanimously approved by the delegates attending the General Meeting at 11:15 a.m. on the same day.

This General Mandate will be noticed to all shareholders who have the rights to attend the meeting.